Avidity Biosciences Inc (RNA)

$72.75 -0.17 (-0.23%)
Market Cap 11.27B
Revenue (ttm) 10.90M
Net Income (ttm) -322.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,956.88%
Debt to Equity Ratio 0.00
Volume 4,512,920
Avg Vol 2,219,330
Day's Range N/A - N/A
Shares Out 154.74M
Stochastic %K 64%
Beta 0.93
Analysts Sell
Price Target $73.83

Company Profile

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac disea...

Industry: Biotechnology
Sector: Healthcare
Phone: 619 876 0700
Address:
10578 Science Center Drive, Suite 125, San Diego, United States
focafoca99
focafoca99 Aug. 13 at 9:08 PM
$RNA Atrium Therapeutics announced Q2 2026 financial results.
0 · Reply
STACKD0E
STACKD0E Aug. 13 at 12:19 PM
👁 $CADL $RNA $FRMM $QUCY $ONDS
0 · Reply
Fred_Sigma_Invest
Fred_Sigma_Invest Aug. 12 at 2:37 PM
$PEPG $VRTX $SRPT $DYN $RNA
0 · Reply
Quantumup
Quantumup Jul. 23 at 12:03 PM
Cantor🏁 $DYN and said -- We are initiating coverage of Dyne Therapeutics (NASDAQ: DYN) with an Overweight rating. $SRPT CAPR SLDB PTCT $RNA PEPG SNY IONS Here's what else Cantor had to say in its initiation report: https://x.com/Quantumup1/status/2080262413471953360?s=20
0 · Reply
STACKD0E
STACKD0E Jul. 21 at 7:02 PM
$RNA ✨️
0 · Reply
ajmrtxl
ajmrtxl Jul. 15 at 1:10 PM
$RNA 's latest data on SqueezeFinder
0 · Reply
dgbio
dgbio Jul. 15 at 2:03 AM
$RNA Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome. https://investors.atriumtherapeutics.com/2026-07-14-Atrium-Therapeutics-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-ATR-1072-for-Treatment-of-PRKAG2-Syndrome
0 · Reply
STACKD0E
STACKD0E Jul. 14 at 9:48 PM
$RNA ✨
0 · Reply
ajmrtxl
ajmrtxl Jul. 8 at 3:48 PM
$RNA 's latest data on SqueezeFinder
0 · Reply
Vandelay_Industries_Inc
Vandelay_Industries_Inc Jul. 7 at 6:24 PM
$RNA This one didn't pan out according to the spinoff thesis. It's a non-core position. Breakeven exit to reposition elsewhere. GLTA
0 · Reply
Latest News on RNA
Atrium Therapeutics earns $15M milestone payment from Bristol Myers

2026-08-17T07:54:26.000Z - 2 days ago

Atrium Therapeutics earns $15M milestone payment from Bristol Myers

BMY

Atrium Therapeutics reports Q2 EPS ($1.18) vs (75c) last year

2026-08-16T14:03:34.000Z - 3 days ago

Atrium Therapeutics reports Q2 EPS ($1.18) vs (75c) last year

Atrium Therapeutics Reports Second Quarter 2026 Financial Results

Aug 13, 2026, 4:44 PM EDT - 5 days ago

Atrium Therapeutics Reports Second Quarter 2026 Financial Results

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

Aug 13, 2026, 8:00 AM EDT - 6 days ago

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

BMY

Atrium Therapeutics initiated with a Buy at H.C. Wainwright

2026-08-06T10:10:23.000Z - 13 days ago

Atrium Therapeutics initiated with a Buy at H.C. Wainwright

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jul 20, 2026, 5:58 PM EDT - 4 weeks ago

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Atrium Therapeutics announces FDA clearance of ATR 1072 IND application

2026-07-14T10:40:25.000Z - 5 weeks ago

Atrium Therapeutics announces FDA clearance of ATR 1072 IND application

Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome

Jul 14, 2026, 6:30 AM EDT - 5 weeks ago

Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome

Atrium Therapeutics Transcript: Transcript

Jul 9, 2026, 1:05 AM EDT - 5 weeks ago

Atrium Therapeutics Transcript: Transcript

Atrium Therapeutics Transcript: Transcript

Jul 9, 2026, 12:33 AM EDT - 5 weeks ago

Atrium Therapeutics Transcript: Transcript

Atrium Therapeutics Transcript: Transcript

Jul 8, 2026, 10:58 PM EDT - 5 weeks ago

Atrium Therapeutics Transcript: Transcript

Atrium Therapeutics Transcript: Transcript

Jul 8, 2026, 5:25 PM EDT - 5 weeks ago

Atrium Therapeutics Transcript: Transcript

Atrium Therapeutics Transcript: Transcript

Jul 8, 2026, 5:03 PM EDT - 5 weeks ago

Atrium Therapeutics Transcript: Transcript

Atrium Therapeutics initiated with an Overweight at Cantor Fitzgerald

2026-06-18T10:56:05.000Z - 2 months ago

Atrium Therapeutics initiated with an Overweight at Cantor Fitzgerald

Atrium Therapeutics initiated with an Overweight at Cantor Fitzgerald

2026-06-18T10:12:23.000Z - 2 months ago

Atrium Therapeutics initiated with an Overweight at Cantor Fitzgerald

Atrium Therapeutics Transcript: Transcript

May 27, 2026, 7:06 AM EDT - 3 months ago

Atrium Therapeutics Transcript: Transcript

Leerink starts ‘interesting preclinical-stage opportunity’ Atrium at Outperform

2026-05-15T16:48:25.000Z - 3 months ago

Leerink starts ‘interesting preclinical-stage opportunity’ Atrium at Outperform

Atrium Therapeutics initiated with an Outperform at Leerink

2026-05-15T10:21:09.000Z - 3 months ago

Atrium Therapeutics initiated with an Outperform at Leerink

Atrium Therapeutics Reports First Quarter 2026 Financial Results

May 14, 2026, 4:40 PM EDT - 3 months ago

Atrium Therapeutics Reports First Quarter 2026 Financial Results

Atrium Therapeutics earns $15M development milestone payment from Bristol Myers

2026-04-23T12:11:08.000Z - 4 months ago

Atrium Therapeutics earns $15M development milestone payment from Bristol Myers

BMY

Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 20, 2026, 10:46 PM EDT - 4 months ago

Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Atrium Therapeutics initiated with an Overweight at Wells Fargo

2026-03-10T20:27:36.000Z - 5 months ago

Atrium Therapeutics initiated with an Overweight at Wells Fargo

Atrium Therapeutics launches as newly independent, publicly traded company

2026-02-27T14:25:20.000Z - 6 months ago

Atrium Therapeutics launches as newly independent, publicly traded company

NVS

Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies

Feb 27, 2026, 9:19 AM EST - 6 months ago

Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies

Novartis completes acquisition of Avidity Biosciences

2026-02-27T14:11:04.000Z - 6 months ago

Novartis completes acquisition of Avidity Biosciences

NVS

Why Is Avidity Biosciences Stock (RNA) Down Today?

2026-02-27T14:07:47.000Z - 6 months ago

Why Is Avidity Biosciences Stock (RNA) Down Today?

NVS

Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Feb 26, 2026, 4:02 PM EST - 6 months ago

Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders

Feb 23, 2026, 8:00 AM EST - 6 months ago

Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders

The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1

Feb 18, 2026, 5:00 PM EST - 6 months ago

The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1

Avidity Biosciences Announces Expected Record Date for Spin-Off

Feb 2, 2026, 9:44 PM EST - 7 months ago

Avidity Biosciences Announces Expected Record Date for Spin-Off

Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development

Jan 28, 2026, 4:15 PM EST - 7 months ago

Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development

SNOA

Pharma sector doubles down on AI amid hopes of slashing costs, timelines

Jan 15, 2026, 11:35 AM EST - 7 months ago

Pharma sector doubles down on AI amid hopes of slashing costs, timelines

AZN GEHC LLY

These 15 stocks are still showing momentum — and a market-beating edge

Nov 20, 2025, 3:45 PM EST - 9 months ago

These 15 stocks are still showing momentum — and a market-beating edge

BE CIEN CRDO GH INSM LITE MP

Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44

Nov 19, 2025, 9:13 AM EST - 9 months ago

Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44

Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights

Nov 10, 2025, 4:05 PM EST - 10 months ago

Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights

Avidity Biosciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avidity Biosciences, Inc. - RNA

Oct 27, 2025, 8:05 PM EDT - 10 months ago

Avidity Biosciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avidity Biosciences, Inc. - RNA

Why Avidity Biosciences And Dyne Therapeutics Stocks Soared 40% Monday

Oct 27, 2025, 12:31 PM EDT - 10 months ago

Why Avidity Biosciences And Dyne Therapeutics Stocks Soared 40% Monday

Is it too late to buy Avidity stock after Novartis deal?

Oct 27, 2025, 10:22 AM EDT - 10 months ago

Is it too late to buy Avidity stock after Novartis deal?

Trump's trade deals, Novartis acquires Avidity, Taco Bell's beverage push and more in Morning Squawk

Oct 27, 2025, 8:16 AM EDT - 10 months ago

Trump's trade deals, Novartis acquires Avidity, Taco Bell's beverage push and more in Morning Squawk

NVS

Novartis shares slip, Avidity soars after $12 billion biotech deal

Oct 27, 2025, 6:29 AM EDT - 10 months ago

Novartis shares slip, Avidity soars after $12 billion biotech deal

NVS

Novartis Agrees $12 Billion Biotech Deal for Avidity

Oct 27, 2025, 4:59 AM EDT - 10 months ago

Novartis Agrees $12 Billion Biotech Deal for Avidity

NVS

Novartis Agrees to Acquire Avidity Biosciences for $12 Billion

Oct 26, 2025, 5:33 PM EDT - 10 months ago

Novartis Agrees to Acquire Avidity Biosciences for $12 Billion

NVS

Novartis to acquire Avidity Biosciences for about $12B

Oct 26, 2025, 3:46 PM EDT - 10 months ago

Novartis to acquire Avidity Biosciences for about $12B

NVS

Novartis Deal Values Avidity Biosciences At $12 Billion

Oct 26, 2025, 3:29 PM EDT - 10 months ago

Novartis Deal Values Avidity Biosciences At $12 Billion

NVS

Novartis to acquire Avidity Biosciences for $12 billion

Oct 26, 2025, 1:07 PM EDT - 10 months ago

Novartis to acquire Avidity Biosciences for $12 billion

NVS

Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG

Oct 26, 2025, 1:07 PM EDT - 10 months ago

Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG

NVS

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline

Oct 26, 2025, 1:00 PM EDT - 10 months ago

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline

NVS

Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports

Oct 26, 2025, 12:26 PM EDT - 10 months ago

Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports

NVS

Novartis nears $70-plus per share deal to acquire Avidity Biosciences, Bloomberg News reports

Oct 26, 2025, 11:09 AM EDT - 10 months ago

Novartis nears $70-plus per share deal to acquire Avidity Biosciences, Bloomberg News reports

NVS

Avidity Biosciences to Participate in Upcoming Investor Conference

Oct 16, 2025, 9:00 AM EDT - 10 months ago

Avidity Biosciences to Participate in Upcoming Investor Conference

Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026

Oct 13, 2025, 9:00 AM EDT - 11 months ago

Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026

Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society

Oct 6, 2025, 9:00 AM EDT - 11 months ago

Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society

Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 15, 2025, 4:01 PM EDT - 1 year ago

Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock

Sep 11, 2025, 7:56 PM EDT - 1 year ago

Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock

Avidity Biosciences Announces Proposed Public Offering of Common Stock

Sep 10, 2025, 4:01 PM EDT - 1 year ago

Avidity Biosciences Announces Proposed Public Offering of Common Stock

Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People Living with DMD44

Sep 10, 2025, 7:00 AM EDT - 1 year ago

Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People Living with DMD44

Avidity Biosciences to Participate in Upcoming Investor Conferences

Aug 27, 2025, 9:00 AM EDT - 1 year ago

Avidity Biosciences to Participate in Upcoming Investor Conferences

Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights

Aug 7, 2025, 4:05 PM EDT - 1 year ago

Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights

Novartis weighs deal for biotech Avidity Biosciences, FT reports

Aug 6, 2025, 11:41 AM EDT - 1 year ago

Novartis weighs deal for biotech Avidity Biosciences, FT reports

NVS

Avidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission

Jul 28, 2025, 9:00 AM EDT - 1 year ago

Avidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission

Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping

Jul 23, 2025, 9:00 AM EDT - 1 year ago

Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping

Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress

Jun 11, 2025, 9:00 AM EDT - 1 year ago

Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress

Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants

Jun 9, 2025, 7:01 AM EDT - 1 year ago

Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants

Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD

Jun 9, 2025, 7:00 AM EDT - 1 year ago

Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 21, 2025, 4:05 PM EDT - 1 year ago

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

focafoca99
focafoca99 Aug. 13 at 9:08 PM
$RNA Atrium Therapeutics announced Q2 2026 financial results.
0 · Reply
STACKD0E
STACKD0E Aug. 13 at 12:19 PM
👁 $CADL $RNA $FRMM $QUCY $ONDS
0 · Reply
Fred_Sigma_Invest
Fred_Sigma_Invest Aug. 12 at 2:37 PM
$PEPG $VRTX $SRPT $DYN $RNA
0 · Reply
Quantumup
Quantumup Jul. 23 at 12:03 PM
Cantor🏁 $DYN and said -- We are initiating coverage of Dyne Therapeutics (NASDAQ: DYN) with an Overweight rating. $SRPT CAPR SLDB PTCT $RNA PEPG SNY IONS Here's what else Cantor had to say in its initiation report: https://x.com/Quantumup1/status/2080262413471953360?s=20
0 · Reply
STACKD0E
STACKD0E Jul. 21 at 7:02 PM
$RNA ✨️
0 · Reply
ajmrtxl
ajmrtxl Jul. 15 at 1:10 PM
$RNA 's latest data on SqueezeFinder
0 · Reply
dgbio
dgbio Jul. 15 at 2:03 AM
$RNA Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome. https://investors.atriumtherapeutics.com/2026-07-14-Atrium-Therapeutics-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-ATR-1072-for-Treatment-of-PRKAG2-Syndrome
0 · Reply
STACKD0E
STACKD0E Jul. 14 at 9:48 PM
$RNA ✨
0 · Reply
ajmrtxl
ajmrtxl Jul. 8 at 3:48 PM
$RNA 's latest data on SqueezeFinder
0 · Reply
Vandelay_Industries_Inc
Vandelay_Industries_Inc Jul. 7 at 6:24 PM
$RNA This one didn't pan out according to the spinoff thesis. It's a non-core position. Breakeven exit to reposition elsewhere. GLTA
0 · Reply
revuelto
revuelto Jul. 6 at 1:48 PM
$RNA looks good to me🎉
0 · Reply
notreload_ai
notreload_ai Jun. 18 at 11:53 AM
BofA initiates coverage on $IMMX with a Buy rating and $27 price target. RBC starts $PRAX with Outperform ($449 PT), while Cantor begins coverage on $RNA. Morgan Stanley downgrades $ENGN to Underweight. https://notreload.xyz/xy/bofa-buy-on-immx-rbc-cantor-bullish-on-prax-rna/
0 · Reply
NVDAMillionaire
NVDAMillionaire Jun. 10 at 2:00 PM
$RNA Outstanding article that hits the mark on RNA's current state. So if you want to refresh your RNA insights or learn about RNA from scratch, this is a must read. https://everyticker.com/quote/RNA/analysis/atrium-therapeutics-a-270m-bet-on-cardiac-rna-delivery-before-clinical-proof-nasdaq-rna
0 · Reply
d_risk
d_risk Jun. 2 at 1:15 PM
$RNA - Avidity Biosciences Inc - 10Q - Updated Risk Factors 🚨 Peer Alert: Risk-factor words are +268.9% above peer average (43,350 vs 11,751 across 654 peers). RNA’s updated 10-Q sharpens early-stage and financing risks: newly public, preclinical-only, loss-making, with an unproven cardiac RNA platform, heavy reliance on Avidity and big-pharma partners, growing regulatory/tax burdens, and fresh warnings on internal controls, market volatility, and potential shareholder litigation. #Biotechnology #EarlyStageRisk #PartnershipDependence #RegulatoryChallenges #MarketVolatility 🟢 Added 🟠 Removed https://d-risk.ai/RNA/10-Q/2026-05-14
0 · Reply
SuperGreenToday
SuperGreenToday May. 21 at 10:55 PM
$RNA Share Price: $13.02 Contract Selected: Jan 15, 2027 $20 Calls Buy Zone: $41.65 – $51.45 Target Zone: $68.35 – $83.54 Potential Upside: 55% ROI Time to Expiration: 238 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Vandelay_Industries_Inc
Vandelay_Industries_Inc May. 15 at 4:35 PM
$RNA ER is fine. No major surprises. Cash burn is reasonable. Stock trades at a 25% discount to cash on balance sheet. Looking forward to 1-2 IND filings in 2H26. Don't see why it shouldn't move higher towards $17+ near term to align with 1x cash.
0 · Reply
focafoca99
focafoca99 May. 14 at 9:18 PM
$RNA launched its Q1 2026 earnings release, reporting results for the quarter ended March 31, 2026.
0 · Reply
BillionerOfKing
BillionerOfKing Apr. 30 at 2:22 PM
$RNA Current Stock Price: $12.96 Contracts to trade: $33.0 RNA Jun 18 2026 Call Entry: $19.50 Exit: $37.65 ROI: 93% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Fingerlickengood
Fingerlickengood Apr. 29 at 1:18 PM
$CDXS $RNA $MRK $IONS https://www.globenewswire.com/news-release/2026/04/29/3283814/24825/en/Codexis-to-share-RNA-manufacturing-advances-at-TIDES-USA.html
2 · Reply
Fingerlickengood
Fingerlickengood Apr. 26 at 3:26 PM
$CDXS $RNA $BMY https://acsgcipr.org/sustainable-manufacturing-of-bms-986278-leveraging-an-ered-kred-biocatalytic-cascade/
1 · Reply
focafoca99
focafoca99 Apr. 21 at 6:55 AM
$RNA granted inducement awards covering 101,250 stock options and 50,625 restricted stock units to seven new non-executive hires.
0 · Reply
DailyWatcher_
DailyWatcher_ Apr. 19 at 2:25 PM
Squeeze Wachlist for Mon Apr 19: - $TRAX.X | First Tracks Biotherapeutics | Spinoff - New Listing - $ANAB | AnaptysBio | First trading post distribution Both have potential to replicate the x4 of $RNA on its Feb 27 debut. Volatility on large caps is a gift!
1 · Reply